Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

An integrative genomic and epigenomic approach for the study of transcriptional regulation.

Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, Fridriksson J, Paietta E, Wiernik P, Green RD, Greally JM, Melnick A.

PLoS One. 2008 Mar 26;3(3):e1882. doi: 10.1371/journal.pone.0001882.

2.

Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.

Saeed S, Logie C, Francoijs KJ, Frigè G, Romanenghi M, Nielsen FG, Raats L, Shahhoseini M, Huynen M, Altucci L, Minucci S, Martens JH, Stunnenberg HG.

Blood. 2012 Oct 11;120(15):3058-68. doi: 10.1182/blood-2011-10-386086. Epub 2012 Aug 24.

3.

Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.

Nouzova M, Holtan N, Oshiro MM, Isett RB, Munoz-Rodriguez JL, List AF, Narro ML, Miller SJ, Merchant NC, Futscher BW.

J Pharmacol Exp Ther. 2004 Dec;311(3):968-81. Epub 2004 Aug 9.

4.

Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.

Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF.

Breast Cancer Res. 2008;10(4):R62. doi: 10.1186/bcr2121. Epub 2008 Jul 18.

5.

Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.

Röhrs S, Dirks WG, Meyer C, Marschalek R, Scherr M, Slany R, Wallace A, Drexler HG, Quentmeier H.

Mol Cancer. 2009 Oct 16;8:86. doi: 10.1186/1476-4598-8-86.

6.

cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia.

Levy-Nissenbaum O, Sagi-Assif O, Raanani P, Avigdor A, Ben-Bassat I, Witz IP.

Methods Enzymol. 2003;366:103-13.

PMID:
14674243
7.

Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.

del Rey M, O'Hagan K, Dellett M, Aibar S, Colyer HA, Alonso ME, Díez-Campelo M, Armstrong RN, Sharpe DJ, Gutiérrez NC, García JL, De Las Rivas J, Mills KI, Hernández-Rivas JM.

Leukemia. 2013 Mar;27(3):610-8. doi: 10.1038/leu.2012.253. Epub 2012 Aug 31.

PMID:
22936014
8.

Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min DJ.

Pediatr Blood Cancer. 2006 Aug;47(2):130-40.

PMID:
16358311
9.

Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.

Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, Saisho H.

J Hepatol. 2004 Sep;41(3):436-45.

PMID:
15336447
10.

MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cells.

Yalcin A, Kreutz C, Pfeifer D, Abdelkarim M, Klaus G, Timmer J, Lübbert M, Hackanson B.

Leuk Res. 2013 Jan;37(1):102-11. doi: 10.1016/j.leukres.2012.09.014. Epub 2012 Oct 11.

PMID:
23062266
11.

Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.

Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, Leu YW, Liu JC, Huang TH.

Cancer Res. 2003 Oct 1;63(19):6178-86.

12.

Induction of ID1 expression and apoptosis by the histone deacetylase inhibitor (trichostatin A) in human acute myeloid leukaemic cells.

Yu WP, Scott SA, Dong WF.

Cell Prolif. 2008 Feb;41(1):86-97. doi: 10.1111/j.1365-2184.2007.00499.x.

PMID:
18211287
13.

Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status.

Silva FP, Swagemakers SM, Erpelinck-Verschueren C, Wouters BJ, Delwel R, Vrieling H, van der Spek P, Valk PJ, Giphart-Gassler M.

Blood. 2009 Oct 1;114(14):3001-7. doi: 10.1182/blood-2009-03-211334. Epub 2009 Aug 7.

14.

Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.

Gebhard C, Schwarzfischer L, Pham TH, Schilling E, Klug M, Andreesen R, Rehli M.

Cancer Res. 2006 Jun 15;66(12):6118-28.

15.

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Andersson A, Edén P, Lindgren D, Nilsson J, Lassen C, Heldrup J, Fontes M, Borg A, Mitelman F, Johansson B, Höglund M, Fioretos T.

Leukemia. 2005 Jun;19(6):1042-50.

PMID:
15843827
16.

New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes.

Kohlmann A, Schoch C, Dugas M, Schnittger S, Hiddemann W, Kern W, Haferlach T.

Leukemia. 2005 Jun;19(6):953-64.

PMID:
15815718
17.
18.

Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.

Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R.

Lab Invest. 2009 Jul;89(7):791-9. doi: 10.1038/labinvest.2009.50. Epub 2009 Jun 8.

19.
20.

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.

Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck-Verschueren CA, Langerak AW, Löwenberg B, Fazzari M, Greally JM, Valk PJ, Melnick A, Delwel R.

Blood. 2009 Mar 19;113(12):2795-804. doi: 10.1182/blood-2008-08-172387. Epub 2009 Jan 23.

Supplemental Content

Support Center